TNFRSF10B and hepatocellular carcinoma: Furthermore, in our previous studies, we showed that bortezomib, by inhibiting the CIP2A/PP2A/p-Akt pathway, could sensitize hepatocellular carcinoma cells to an antihuman death receptor 5 antibody, CS-1008 [48], and could enhance radiation-induced apoptosis in cervical cancer and hepatocellular carcinoma cells [52].